These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 30905677)

  • 1. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review.
    Hall ET; Singhal S; Dickerson J; Gabster B; Wong HN; Aslakson RA; Schapira L;
    J Pain Symptom Manage; 2019 Jul; 58(1):137-156.e1. PubMed ID: 30905677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials.
    Faury S; Foucaud J
    PLoS One; 2020; 15(1):e0227344. PubMed ID: 31978145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
    Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
    JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
    Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
    Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Immunotherapy on Quality-of-Life Outcomes in Patients with Gastroesophageal Cancers: A Meta-Analysis of Randomized Controlled Trials.
    Gupta K; Roy AM; Attwood K; Nipp RD; Mukherjee S
    Healthcare (Basel); 2024 Jul; 12(15):. PubMed ID: 39120199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
    Musoro JZ; Bottomley A; Coens C; Eggermont AM; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Brandberg Y;
    Eur J Cancer; 2018 Nov; 104():169-181. PubMed ID: 30359910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes with nivolumab in advanced solid cancers.
    Tykodi SS; Schadendorf D; Cella D; Reck M; Harrington K; Wagner S; Shaw JW
    Cancer Treat Rev; 2018 Nov; 70():75-87. PubMed ID: 30125799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.
    Abdel-Rahman O; Oweira H; Giryes A
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1231-1239. PubMed ID: 30253680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors: A cross-sectional study.
    Wang H; Dong Y; Fan T; Zhu S; Zhou Y; Song Y; Pan S; Wu Q; Li Y; Han Y
    Eur J Oncol Nurs; 2024 Feb; 68():102507. PubMed ID: 38219475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
    Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
    Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Gonzalez BD; Eisel SL; Bowles KE; Hoogland AI; James BW; Small BJ; Sharpe S; Hyland KA; Bulls HW; Christy SM; Mansfield J; Nelson AM; Alla R; Maharaj K; Kennedy B; Lafranchise E; Williams NL; Jennewein S; Oswald LB; Postow MA; Dicker AP; Jim HSL
    J Natl Cancer Inst; 2022 Jun; 114(6):808-818. PubMed ID: 34508604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study.
    Cotté FE; Voillot P; Bennett B; Falissard B; Tzourio C; Foulquié P; Gaudin AF; Lemasson H; Grumberg V; McDonald L; Faviez C; Schück S
    J Med Internet Res; 2020 Sep; 22(9):e19694. PubMed ID: 32915159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between age and patient-reported outcomes, emergency department visits, and hospitalizations among lung cancer patients receiving immune checkpoint inhibitors.
    Fleszar-Pavlovic SE; Natori A; Moreno PI; Medina HN; Sookdeo V; MacIntyre J; Penedo FJ
    Psychooncology; 2024 Jan; 33(1):e6293. PubMed ID: 38282219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.